The Claim
In very high-risk cardiovascular patients, combination lipid-lowering therapy with statins and ezetimibe results in a significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) levels compared to statin monotherapy, with a mean difference of -12.96 mg/dL (95% CI: -17.27 to -8.65), supporting more effective achievement of LDL-C treatment goals in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people at very high risk of heart problems, taking cholesterol-lowering drugs called statins plus another drug called ezetimibe lowers bad cholesterol more than taking statins alone — by about 13 points on average — and helps them hit their cholesterol targets better.
See the scientific wording
In very high-risk cardiovascular patients, combination lipid-lowering therapy with statins and ezetimibe is associated with a significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) levels compared to statin monotherapy, with a mean difference of -12.96 mg/dL (95% CI: -17.27 to -8.65), which supports more effective achievement of LDL-C goals in high-risk populations.
What the research says
1 studyThe study looked at whether adding ezetimibe to statins helps lower bad cholesterol more in high-risk heart patients—and it did, just as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.